chufangao/CTO huggingface dataset:
Clinical trial NCT04240210: Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
Official title: SymITA: Switch to DRV/COB/FTC/TAF From Integrase Containing Regimens to Evaluate Changes in Tolerability/Adherence
Acronym: SymITA
Sponsor: Midland Research Group, Inc. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Lack of eligible enrollees/ Halted by Primary Sponsor
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-17
Primary completion date: 2021-12-01
Completion date: 2021-12-01
Clinical trial NCT03772249: Study of Safety and Tolerability of DCR HBVS
Official title: A Three-Part, Phase 1, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DCR-HBVS in Healthy Volunteers and Patients With Chronic Hepatitis B
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 82.0 (ACTUAL)
Number of arms: 22.0
Start date: 2018-12-28
Primary completion date: 2022-07-12
Completion date: 2022-07-12
Clinical trial NCT04876521: Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression
Official title: Comparative Efficacy and Safety of Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in the Treatment of Post Schizophrenic Depression: A Randomized Controlled Trial
Acronym: PSD-AOFC
Sponsor: All India Institute of Medical Sciences, Bhubaneswar (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-14
Primary completion date: 2021-06-09
Completion date: 2021-06-30
Limitations and caveats: 1. Small sample size~2. Single-center study~3. No control arm for comparing the Serum BDNF levels
Plan to share individual participant data: NO
IPD sharing description: To maintain the confidentiality of the participants.
Clinical trial NCT04588246: Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
Official title: Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS With Brain Metastasis Velocity &gt;/= 4 Brain Metastases/Year
Sponsor: NRG Oncology (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Accrual target will not be met.
Enrollment: 19.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-15
Primary completion date: 2024-08-06
Completion date: 2024-08-06
Clinical trial NCT04458909: Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
Official title: An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: External information
Enrollment: 15.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-09
Primary completion date: 2023-08-15
Completion date: 2023-08-15
Baseline population: Randomized participants
Limitations and caveats: This study stopped accrual early at 15 participants of the 316 planned, due to published results of two other studies resolving the study question. As less than 5% of the sample size was accrued, no statistical testing was done.
Plan to share individual participant data: YES
IPD sharing description: NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Clinical trial NCT04100083: Spironolactone for Hidradenitis Suppurativa
Official title: Spironolactone in the Treatment of Hidradenitis Suppurativa: a Prospective, Open-Label Proof-of-Concept and Dose-Ranging Study
Sponsor: Medical University of South Carolina (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-09-21
Primary completion date: 2021-06-21
Completion date: 2021-06-21
Plan to share individual participant data: NO
Clinical trial NCT03365414: A Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe POTS
Official title: A Double Blind Randomized Controlled Crossover Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe Postural Orthostatic Tachycardia Syndrome
Sponsor: University of Alberta (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Withdrawal of support of product for trial
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-31
Primary completion date: 2023-10-31
Completion date: 2024-03-31
Plan to share individual participant data: NO
IPD sharing description: There is no plan to share individual participant data (IPD) available with other researchers.
Clinical trial NCT05635461: Relative Bioavailability and Food Effect Study of CVN424
Official title: A Randomized, Open-Label, Single Oral Dose, Three-Way Cross-Over Trial to Evaluate the Relative Bioavailability of CVN424 Suspension &Tablet Formulations Including an Assessment of the Effect of Food on the Tablet Formulation in Healthy Adult Volunteers
Sponsor: Cerevance (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 32.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-10-09
Primary completion date: 2022-11-11
Completion date: 2022-11-21
Baseline population: Safety Analysis Set consisted of all participants who were enrolled and received study drug.
Plan to share individual participant data: NO
Clinical trial NCT03453164: Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)
Official title: Combination of Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer After Initial Treatment With Standard Therapy (CIRCUIT).
Sponsor: Fukushima Medical University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 41.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-28
Primary completion date: 2021-01-07
Completion date: 2021-01-31
Baseline population: A total of 41 patients enrolled in this study were subjected to the safety analysis, and 40 patients, excluding one ineligible patient (72 years old, male), were subjected to the efficacy analysis.
Plan to share individual participant data: NO
Clinical trial NCT02481830: Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer
Official title: An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)
Acronym: CheckMate331
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 569.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-09-14
Primary completion date: 2018-08-17
Completion date: 2022-08-30
Baseline population: All Randomized Participants
Clinical trial NCT05879185: A Study of XmAb23104 in People With Sarcoma
Official title: Phase II Study of XmAb23104 (Targeting PD-1 and ICOS), in Patients With Advanced Sarcoma
Sponsor: Memorial Sloan Kettering Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Vendor decided study to be closed early
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-04-06
Primary completion date: 2024-07-19
Completion date: 2024-07-19
Plan to share individual participant data: YES
IPD sharing description: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Clinical trial NCT03755934: Efficacy and Safety of MEDI7352 in Participants With Painful Diabetic Neuropathy
Official title: A Randomised, Double-Blind, Placebo-Controlled, Dose-Response Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was prematurely terminated due to longer enrolment time than was anticipated.
Enrollment: 112.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-11-19
Primary completion date: 2023-06-29
Completion date: 2023-06-29
Baseline population: The Screening Population includes all participants who were enrolled and provided informed consent and demographic and/or baseline screening assessments.
Limitations and caveats: Dose-response relationship outcome was not evaluated by MCP-MOD because of insufficient number of doses. The study was prematurely terminated due to longer enrolment time than was anticipated. A combined population PK analysis was reported separately from the main CSR as a stand-alone report.
Clinical trial NCT03919773: IVIG (Gamunex-C) Treatment Study for POTS Subjects
Official title: IVIG (Gamunex-C) Study of Treatment for Autoimmune Neuropathic Dysautonomia/Postural Tachycardia (POTS)
Acronym: iSTAND
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-29
Primary completion date: 2023-06-26
Completion date: 2023-12-01
Plan to share individual participant data: NO
IPD sharing description: All patient information will be de-identified if sent out. Any AE and/or SAE will be sent out for review.
Clinical trial NCT04764448: A Study of Belcesiran in Patients With AATLD
Official title: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Acronym: ESTRELLA
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Development project was discontinued
Enrollment: 16.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-02-12
Primary completion date: 2023-12-08
Completion date: 2024-05-29
Clinical trial NCT00499616: Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
Official title: Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma
Sponsor: Children's Oncology Group (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 464.0 (ACTUAL)
Number of arms: 4.0
Start date: 2007-10-08
Primary completion date: 2014-06-30
Completion date: 2021-06-30
Clinical trial NCT04877080: CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL
Official title: Exploratory Study to Evaluate Efficacy and Safety of Fast Dual CAR-T Injection in CD19+ Refractory or Relapsed B Cell Non-Hodgkinlymphoma
Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: The PI decides to withdraw the research.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-05-05
Primary completion date: 2023-06-30
Completion date: 2023-12-31
Clinical trial NCT05121766: Feasibility Pilot Clinical Trial of Omega-3 Supplement vs. Placebo for Post Covid-19 Recovery Among Health Care Workers
Official title: Feasibility Pilot Clinical Trial of Omega-3 (EPA+DHA) Supplement vs. Placebo for Post-Acute Sequelae of Coronavirus-19 (COVID-19) Recovery Among Health Care Workers
Sponsor: Hackensack Meridian Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Challenges in enrollment
Enrollment: 32.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-10
Primary completion date: 2023-04-21
Completion date: 2023-04-21
Baseline population: Patients consented into the study
Plan to share individual participant data: NO
Clinical trial NCT04439539: A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection
Official title: A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate Efficacy, Pharmacokinetics, Safety, and Tolerability of Treatment With JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog With or Without JNJ-56136379 in Treatment-naive Patients With HBeAg Positive Chronic Hepatitis B Virus Infection
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 54.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-14
Primary completion date: 2023-08-29
Completion date: 2024-02-13
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu
Clinical trial NCT03524612: A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP
Official title: A Phase II, Open-label, Prospective, Single-arm, Study to Assess Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP Who Are Refractory or Relapsed After First-line Steroids
Acronym: TAPER
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 105.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-11-02
Primary completion date: 2021-10-22
Completion date: 2022-10-03
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03955146: Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Sponsor: FibroGen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study did not meet its primary endpoint.
Enrollment: 393.0 (ACTUAL)
Number of arms: 6.0
Start date: 2019-06-18
Primary completion date: 2023-03-20
Completion date: 2023-08-28
Baseline population: The intent-to-treat (ITT) population included all randomized participants.
Limitations and caveats: Study did not meet its primary endpoint; hence, it was terminated early. The Japan extension cohort and OLE period were halted due to futility.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04965818: Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
Official title: A Phase 1b/2 Open-label, Nonrandomized Study of FGFR Inhibitor Futibatinib in Combination With MEK-inhibitor Binimetinib in Patients With Advanced KRAS Mutant Cancer
Sponsor: Taiho Oncology, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Strategic decision by sponsor.
Enrollment: 38.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-09-20
Primary completion date: 2023-06-11
Completion date: 2023-09-21
Clinical trial NCT02728102: Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
Official title: Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma With or Without Vaccination With Dendritic Cell/Myeloma Fusions (BMT CTN 1401)
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 203.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-07-31
Primary completion date: 2020-06-30
Completion date: 2022-12-09
Plan to share individual participant data: YES
IPD sharing description: Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).
IPD time frame: Within 6 months of official study closure at participating sites.
IPD access criteria: Available to the public
Clinical trial NCT04176653: Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124
Official title: Phase 1b Single Ascending and Multiple Dose First-in-man Study in Adult Patients With Non-transfusion-dependent Beta-thalassaemia or Low Risk Myelodysplastic Syndrome to Investigate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of SLN124
Sponsor: Silence Therapeutics plc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Study stopped prior to subject administered first dose, due to COVID-19
Enrollment: 0.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-08-20
Primary completion date: 2021-09-30
Completion date: 2021-10-14
Plan to share individual participant data: NO
Clinical trial NCT03338660: Platelet Function With Various Storage Techniques
Official title: The Impact of Various Storage Techniques on Platelet Function
Sponsor: Northwell Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Unable to begin study due to funding. PI has left organization.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-07-15
Primary completion date: 2019-07-15
Completion date: 2020-07-15
Plan to share individual participant data: NO
Clinical trial NCT05253209: A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects
Official title: A Phase III Double-Blind, Randomized, Placebo Controlled, Multi Center Clinical Study to Evaluate the Efficacy and Safety of Intravenous L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects
Sponsor: Asklepion Pharmaceuticals, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Interim Analysis triggered futility
Enrollment: 64.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-29
Primary completion date: 2024-05-10
Completion date: 2024-05-10
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05094206: CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies
Official title: Phase I Trial of Anti-CD20, Anti-CD19, Anti-CD22 CAR (CAR20.19.22) T-cells for Relapsed, Refractory B-cell Malignancies
Sponsor: Medical College of Wisconsin (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Treated four patients: 2 at a dose of 1x10\^6 cells/kg and 2 ad at dose of 2.5x10\^6 cells/kg. All four patients had no in-vivo expansion and no meaningful response to therapy. At this point per FDA guidance we will not be treating more patients.
Enrollment: 4.0 (ACTUAL)
Number of arms: 10.0
Start date: 2022-06-30
Primary completion date: 2024-01-29
Completion date: 2024-01-29
Plan to share individual participant data: NO
Clinical trial NCT04475198: Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427 IV Infusion in Healthy Subjects
Sponsor: SiteOne Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: strategic decision
Enrollment: 24.0 (ACTUAL)
Number of arms: 5.0
Start date: 2021-03-04
Primary completion date: 2021-08-18
Completion date: 2021-08-18
Plan to share individual participant data: NO
Clinical trial NCT06424236: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation
Official title: A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Acronym: DIAN-TU
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: DIAN-TU announced the discontinuation of the DIAN-TU-001 OLE based on findings from an interim efficacy analysis and the status of the drug program.
Enrollment: 73.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-30
Primary completion date: 2023-10-06
Completion date: 2023-11-13
Plan to share individual participant data: YES
IPD sharing description: Access to DIAN-TU trial data will follow the DIAN-TU data access policy, which complies with the guidelines established by the Collaboration for Alzheimer's Prevention \[CAP REF\].
Clinical trial NCT02002598: Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Official title: Phase I/II Study of Carfilzomib in Combination With Bendamustine and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Slow accrual and loss of funding
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-11-30
Primary completion date: 2019-03-01
Completion date: 2023-07-01
Baseline population: Data was collected and analyzed as one arm for this single-arm study. Additionally, presented as one arm to protect the confidentiality of the first four participants.
Limitations and caveats: The limitations of this study include a small sample size, failure to complete planned accrual, and lack of high cytogenetic risk patients.
Plan to share individual participant data: NO